TG Therapeutics (STU:NKB2) Debt-to-Asset : 0.30 (As of Mar. 2024)

View and export this data going back to 2015. Start your Free Trial

What is TG Therapeutics Debt-to-Asset?

TG Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was €1.3 Mil. TG Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was €101.5 Mil. TG Therapeutics's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Mar. 2024 was €343.5 Mil. TG Therapeutics's debt to asset for the quarter that ended in Mar. 2024 was 0.30.

TG Therapeutics Debt-to-Asset Historical Data

The historical data trend for TG Therapeutics's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TG Therapeutics Debt-to-Asset Chart

TG Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Asset

Get a 7-Day Free Trial

0.25

0.07

0.21

0.43

0.34

TG Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Asset	Get a 7-Day Free Trial															0.55	0.49	0.33	0.34	0.30

Competitive Comparison of TG Therapeutics's Debt-to-Asset

For the Biotechnology subindustry, TG Therapeutics's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

TG Therapeutics's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, TG Therapeutics's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where TG Therapeutics's Debt-to-Asset falls into.

TG Therapeutics Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

TG Therapeutics's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(1.326	+	100.273)	/	302.231
	=	0.34

TG Therapeutics's Debt-to-Asset for the quarter that ended in Mar. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(1.272	+	101.463)	/	343.457
	=	0.30

TG Therapeutics (STU:NKB2) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

TG Therapeutics Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of TG Therapeutics's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

TG Therapeutics (STU:NKB2) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TG Therapeutics Inc (STU:NKB2) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

TGTX:USA NKB2:Germany

Address

3020 Carrington Mill boulevard, Suite 475, Morrisville, NC, USA, 27560

Website

https://www.tgtherapeutics.com

TG Therapeutics Inc is a fully-integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). and the company is developing TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders which are under Phase 1 trial.

TG Therapeutics (STU:NKB2) Headlines

No Headlines